Testing effectiveness (Phase 2)Ended earlyNCT04634825
What this trial is testing
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Who this might be right for
Head and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell Carcinoma
MacroGenics 62